Danger of mRNA vaccines to elderly under spotlight after 16 deaths in Switzerland
Published: Feb 28, 2021 05:50 PM
File photo:Xinhua

File photo:Xinhua

The deaths of 16 elderly people in Switzerland after being inoculated with Pfizer and Moderna COVID-19 vaccines underscore the potential danger of mRNA vaccines to the age group, Chinese vaccine experts said, further calling for caution.

At least 16 people died after receiving vaccines in Switzerland, the Swiss Agency for Therapeutic Products (Swissmedic) was quoted as saying by Sputnik in a report on Saturday.

The agency said it had obtained about 364 suspected adverse drug reactions, with 199 incidents linked to the vaccines developed by Pfizer and BioNTech, and 154 to Moderna's drug, said the report. 

Swissmedic said the average age of the deaths was 86 and most of them had pre-existing diseases, adding there was no evidence to suggest that the vaccines were the cause of death. 

Chinese experts said the incidents should be assessed cautiously to understand whether the deaths were caused by the vaccines or other preexisting conditions in these individuals. 

Previously, Norway reported 23 deaths in connection with vaccinations, all of whom were over 80 years old. The COVID-19 vaccines from BioNTec/Pfizer and Moderna were used in Norway.

A Chinese immunologist who requested anonymity told the Global Times that the large-scale use of mRNA vaccines carries the risk of causing abnormal immune dysfunction, allergy or even death, especially among the elderly and people with underlying diseases.

The immunologist suggested individuals with preexisting conditions, the elderly and those with vulnerable immunity not be given vaccines.

The Global Times found that major Western media outlets have been downplaying the deaths relating to the Pfizer and Moderna vaccines, and also the 16 deaths in Switzerland. 

Some observers questioned the veracity of declarations that the sporadic deaths were unrelated to the vaccines, calling on Western media to report the deaths fairly.

Global Times